Análisis Argos
HCC
HCCSin veredicto2 señales de riesgo
Warrior Met Coal, Inc. · Energy
US$ 80.83
precio al 2026-07-04
Valor justo Argos*
Sin estimar
vs. su valor justo
Sin estimar
Score Argos
26/100
Sin veredicto
LA RESPUESTA
No tenemos un veredicto de valuación confiable acá: su flujo de caja no permite una estimación sólida. Mirá su calidad y su salud para formarte una idea — preferimos eso a inventarte un número.
Recompensas
✓Tiene más caja que deuda: balance fuerte.
Riesgos
!Beneish M-Score sugiere manipulación (2.92)
!FCF negativo con deuda creciente
VALOR1/6FUTURO4/6PASADO0/6SALUD3/6DIVIDENDO2/6
El Iris de calidad
VALOR1/6FUTURO4/6PASADO0/6SALUD3/6DIVIDENDO2/6
ValorCotiza por encima de su valor justo
FuturoIngresos creciendo con fuerza
PasadoHistorial débil
SaludBalance razonable
DividendoRetorno al accionista moderado
Score Argos26de 100Sin veredicto
Ingresos▼14%
US$ 1.3 B
Margen operativo▼79%
3.5%
Flujo de caja libre▲0%
US$ -0.1 B
Deuda neta
US$ -0 B
Lo esencial, sin ruido
Cap. de mercadoUS$ 4.3B
P/E74.9x
EV/EBITDA18x
FCF yield-2.1%
ROIC2.2%
Margen operativo3.5%
Crecim. ingresos-14.1%/año
Piotroski F4/9
Competidores

Los rivales, con el mismo ojo

El Iris de calidad de cada competidor, lado a lado. Tocá uno para ver su análisis.

Novedades

Noticias recientes

gurufocus.com · 10 jun
TriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug Delivery™ in Liver Cancer
TriSalus Life Sciences, Inc. (Nasdaq: TLSI), an oncology company integrating novel delivery technology with standard-of-care therapies and an investigational i
gurufocus.com · 9 jun
Warrior Met Coal Inc (HCC) Shares Fall 4.3% -- What GF Score of 81 Tells Investors
On June 09, 2026, Warrior Met Coal Inc (HCC) shares fell 4.3% to a current price of $94.67, continuing a downward trend noted over the past week with a decline
gurufocus.com · 30 may
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026
[url="]Exelixis, Inc.[/url] (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal trial, which showed that CABOMETYXÂ
gurufocus.com · 29 may
FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that calderasib (MK-1084), an investigational oral specific KRAS G12C inhibi
gurufocus.com · 28 may
IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
AstraZeneca's IMFINZIÂ (durvalumab) in combination with Bacillus Calmette-GuÃrin (BCG) induction and maintenance therapy has been approved in the US for the
fool.com · 7 may
This $4 Million Warrior Met Coal Sale May Be More About Profit Taking Than Coal Prices
Warrior Met Coal supplies high-grade metallurgical coal to global steelmakers, leveraging underground mining operations in Alabama.
seekingalpha.com · 30 abr
Warrior Met Coal, Inc. (HCC) Q1 2026 Earnings Call Transcript
Warrior Met Coal, Inc. (HCC) Q1 2026 Earnings Call Transcript
zacks.com · 30 abr
Warrior Met Coal (HCC) Tops Q1 Earnings and Revenue Estimates
Warrior Met Coal (HCC) came out with quarterly earnings of $1.37 per share, beating the Zacks Consensus Estimate of $1.21 per share. This compares to a loss of $0.16 per share a year ago.

* Valor justo Argos: estimación educativa del valor intrínseco según el propio flujo de caja de la empresa y su capacidad de crecimiento — no un precio objetivo ni una recomendación. Esto es información y educación, no asesoría de inversión. Rendimiento pasado no garantiza resultados futuros.